Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Biosimilars are gradually making inroads in the outpatient drug ...

Prescriptions for an adalimumab biosimilar among new users rose from 0% to 24% after CVS Caremark added it to its formulary, ...

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic drugmaker Samsung Bioepis said in a new report on Thursday as the blockbuster ...

Biosimilars demonstrate comparable drug survival and safety with adalimumab among new users, but patients switching from Humira (the originator product) to biosimilars had a 35% higher discontinuation ...

High- and low-concentration interchangeable biosimilar will be available, estimated to save individual patients around $3,500 on average per year Biosimilar price will be about 85% lower than Humira ® ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Biosimilars offer clinically effective treatment alternatives to ...

Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a blockbuster, appears to have led to a dramatic drop in net spending for these ...

Amgen on Thursday settled a patent lawsuit with Abbvie over its biosimilar version of Abbvie’s best-selling arthritis drug Humira, reports Reuters. The settlement will delay the launch of Amgen’s ...

We can start with laws that limit the power of pharmacy-benefit managers ...

The expanded interchangeability now applies to the 40mg prefilled syringe and the 40mg and 80mg autoinjectors, in addition to the 20mg and 80mg prefilled syringes. The Food and Drug Administration ...